ArticleScientific reports2019
The prognostic significance of MRI-detected extramural venous invasion, mesorectal extension, and lymph node status in clinical T3 mid-low rectal cancer.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Baseline MRI predictors of successful organ preservation in the Organ Preservation in Rectal Adenocarcinoma (OPRA) trial.The British journal of surgery · 2024Trial
- Artificial intelligence for evaluation of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer.PLOS digital health · 2026Article
- MRI assessment of extramural venous invasion in rectal cancer: a practical pictorial review.Abdominal radiology (New York) · 2026Review
- A simple MRI/PET-derived index predicts relapse-free survival after neoadjuvant chemoradiotherapy in locally advanced rectal cancer.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026Article
- A pre-trained foundation model framework for multiplanar MRI classification of extramural vascular invasion and mesorectal fascia invasion in rectal cancer.Insights into imaging · 2026Article
- MRI for prognosis prediction of T3-stage rectal cancer based on "DISTANCE" structural report.Abdominal radiology (New York) · 2026Article
- Integrating perioperative inflammation and pathological invasiveness to predict recurrence after curative colorectal cancer surgery: a multicenter cohort study.Frontiers in oncology · 2026Article
- Identifying baseline rectal MRI features as predictive indicators for local recurrence and metastatic disease in rectal cancer treated with surgical resection and neoadjuvant therapy or surgical resection alone.European journal of radiology · 2025Article
- Development and validation of a multi-parametric MRI deep-learning model for preoperative lymphovascular invasion evaluation in rectal cancer.Quantitative imaging in medicine and surgery · 2025Article
- Aorta and tracheobronchial invasion in esophageal cancer: comparing diagnostic performance of 3.0-T MRI and CT.European radiology · 2023Article
- MRI Assessment of Extramural Venous Invasion Before and After Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer and Its Association with Disease-Free and Overall Survival.Annals of surgical oncology · 2023Article
- Diffusion kurtosis imaging and MRI-detected extramural venous invasion in rectal cancer: correlation with clinicopathological prognostic factors.Abdominal radiology (New York) · 2023Article
- Interobserver variability in MRI measurements of mesorectal invasion depth in rectal cancer.Abdominal radiology (New York) · 2022Article
- MRI-detected extramural venous invasion of rectal cancer: Multimodality performance and implications at baseline imaging and after neoadjuvant therapy.Insights into imaging · 2021Review
- Prognostic Significance of EMVI in Rectal Cancer in a Tertiary Cancer Hospital in India.The Indian journal of radiology & imaging · 2021Article
- MRI Evaluation of Extramural Venous Invasion (EMVI) with Rectal Carcinoma Using High Resolution T2 and Combination of High Resolution T2 and Contrast Enhanced T1 Weighted Imaging.Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH · 2021Article
- Histogram Analysis of Diffusion-Weighted Magnetic Resonance Imaging as a Biomarker to Predict Lymph Node Metastasis in T3 Stage Rectal Carcinoma.Cancer management and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to evaluate the prognostic significance of the magnetic resonance imaging-detected extramural venous invasion (MR-EMVI), the depth of mesorectal extension (MR-DME), and lymph node status (MR-LN) in clinical T3 mid-low rectal cancer. One hundred and forty-six patients with clinical T3 mid-low rectal cancer underwent curative surgery were identified. Pretreatment high-resolution MRI was independently reviewed by two experienced radiologists to evaluate MR-EMVI score (0-4), MR-DME (≤4 mm or >4 mm), and MR-LN (positive or negative). The Cox-multivariate regression analysis revealed that the MR-EMVI was the only independent prognostic factor that correlated with overall 3-year disease-free survival (DFS) (p = 0.01). The survival analysis showed that patients with positive MR-EMVI, MR-DME > 4 mm, and positive MR-LN had a poorer prognosis in the overall 3-year DFS (HR 3.557, 95% CI 2.028 to 13.32, p < 0.01; HR 3.744, 95% CI:1.165 to 5.992, p = 0.002; HR 2.946, 95% CI: 1.386 to 6.699, p < 0.01). By combining MR-EMVI with MR-DME or MR-LN, the prognostic significance was more remarkable. Our study suggested that the MR-EMVI, MR-DME, and MR-LN were the important prognostic factors for patients with clinical T3 mid-low rectal cancer and the MR-EMVI was an independent prognostic factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.